מקטובי 15מג ישראל - עברית - Ministry of Health

מקטובי 15מג

medison pharma ltd - binimetinib - טבליות מצופות פילם - binimetinib 15 mg - binimetinib

ברפטובי 75 מג ישראל - עברית - Ministry of Health

ברפטובי 75 מג

medison pharma ltd - encorafenib - קפסולות ג'לטין קשיחות - encorafenib 75 mg - encorafenib

מקיניסט 0.5 מג ישראל - עברית - Ministry of Health

מקיניסט 0.5 מג

novartis israel ltd - trametinib as dimethyl sulfoxide - טבליות מצופות פילם - trametinib as dimethyl sulfoxide 0.5 mg - trametinib

מקיניסט 2 מג ישראל - עברית - Ministry of Health

מקיניסט 2 מג

novartis israel ltd - trametinib as dimethyl sulfoxide - טבליות מצופות פילם - trametinib as dimethyl sulfoxide 2 mg - trametinib

קוטליק ישראל - עברית - Ministry of Health

קוטליק

roche pharmaceuticals (israel) ltd - cobimetinib as hemifumarate - טבליות מצופות פילם - cobimetinib as hemifumarate 20 mg

סוטנט 12.5 מג ישראל - עברית - Ministry of Health

סוטנט 12.5 מג

pfizer pharmaceuticals israel ltd - sunitinib as malate - קפסולות - sunitinib as malate 12.5 mg - sunitinib - sunitinib - sutent is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sutent is indicated for the treatment of advanced renal cell carcinoma.treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.

סוטנט 25 מג ישראל - עברית - Ministry of Health

סוטנט 25 מג

pfizer pharmaceuticals israel ltd - sunitinib as malate - קפסולות - sunitinib as malate 25 mg - sunitinib - sunitinib - sutent is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sutent is indicated for the treatment of advanced renal cell carcinoma.treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.

סוטנט 50 מג ישראל - עברית - Ministry of Health

סוטנט 50 מג

pfizer pharmaceuticals israel ltd - sunitinib as malate - קפסולות - sunitinib as malate 50 mg - sunitinib - sunitinib - sutent is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sutent is indicated for the treatment of advanced renal cell carcinoma.treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.

טסיגנה 200 מג ישראל - עברית - Ministry of Health

טסיגנה 200 מג

novartis israel ltd - nilotinib as monohydrate - קפסולות - nilotinib as monohydrate 200 mg - nilotinib - nilotinib - treatment of philadelphia chromosome positive chronic myeloid leukaemia (ph+ cml) in chronic or accelerated phase in patients resistant to or experiencing significant toxicity during treatment with imatinib.treatment of adult patients with newly diagnosed philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.

טסיגנה 150 מג ישראל - עברית - Ministry of Health

טסיגנה 150 מג

novartis israel ltd - nilotinib as hydrochloride monohydrate - קפסולות - nilotinib as hydrochloride monohydrate 150 mg - nilotinib - nilotinib - treatment of adult patients with newly diagnosed philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.